Soligenix Seeks CEPI Funding for BDBV Vaccine as Outbreak Reaches 397 Cases
Updated
Updated · PR Newswire · Jun 8
Soligenix Seeks CEPI Funding for BDBV Vaccine as Outbreak Reaches 397 Cases
1 articles · Updated · PR Newswire · Jun 8
Summary
June 12 is the deadline for Soligenix’s planned CEPI application to fund rapid development of a protein-based, thermostable Bundibugyo virus vaccine with the University of Hawaiʻi.
The bid leans on prior filovirus vaccine work showing broad immune responses in mice, up to 100% protection in non-human primates, and compatibility with a key Bundibugyo antigen.
At least 2 years of stability at 40C is central to the pitch, with Soligenix arguing its single-vial, freeze-dried subunit vaccine could ease storage and distribution in African outbreak settings.
The funding push comes as the Bundibugyo outbreak in the Democratic Republic of Congo and Uganda has reached 397 confirmed cases and 65 deaths, after the WHO declared a global health emergency on May 16.
No approved vaccine exists for Bundibugyo, Sudan or Marburg virus, and Soligenix said there is no assurance CEPI will select or fund its proposal.
With three rival vaccines already funded, can Soligenix's heat-stable shot win the race to stop the Bundibugyo outbreak?
A heat-proof vaccine is a breakthrough, but can it overcome the real-world barriers of trust and access to stop the outbreak?
Is the race for a Bundibugyo vaccine a sign of progress, or proof we are still failing at pandemic preparedness?
Bundibugyo Ebola Outbreak: How Market Failure and Vaccine Delays Threaten Global Health Security in 2026
Overview
The Bundibugyo Ebola outbreak in early June 2026 is a severe and fast-moving public health crisis, driven by the Bundibugyo virus—a highly fatal, zoonotic disease. The outbreak is spreading rapidly in a region already weakened by ongoing conflict and fragile health systems, making the situation even more critical. With no approved vaccines or specific treatments available, the response relies on strengthening healthcare capacity, accelerating testing, and ensuring access to essential medical services in affected communities. The coming weeks are crucial for controlling the outbreak and preventing further escalation.